Cargando…

Discordance in HER2 Status in Gastro-esophageal Adenocarcinomas: A Systematic Review and Meta-analysis

Trastuzumab combined with chemotherapy is standard of care for HER2 positive advanced gastro-esophageal cancers. The reported prevalence of HER2 discordance between primary tumors and corresponding metastases varies, hampering uniform patient selection for HER2 targeted therapy. This meta-analysis e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Creemers, A., ter Veer, E., de Waal, L., Lodder, P., Hooijer, G. K. J., van Grieken, N. C. T., Bijlsma, M. F., Meijer, S. L., van Oijen, M. G. H., van Laarhoven, H. W. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5466678/ https://www.ncbi.nlm.nih.gov/pubmed/28600510 http://dx.doi.org/10.1038/s41598-017-03304-9

Ejemplares similares

The dynamics of HER2 status in esophageal adenocarcinoma
por: Creemers, Aafke, et al.
Publicado: (2018)

Tumor‐immune landscape patterns before and after chemoradiation in resectable esophageal adenocarcinomas
por: Soeratram, Tanya TD, et al.
Publicado: (2021)

A systematic review and meta-analysis of prognostic biomarkers in resectable esophageal adenocarcinomas
por: Creemers, Aafke, et al.
Publicado: (2018)

The Use of (Network) Meta-Analysis in Clinical Oncology
por: ter Veer, Emil, et al.
Publicado: (2019)

The efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer: a systematic review and meta-analysis
por: ter Veer, Emil, et al.
Publicado: (2016)

Optimal first-line chemotherapeutic treatment in patients with locally advanced or metastatic esophagogastric carcinoma: triplet versus doublet chemotherapy: a systematic literature review and meta-analysis
por: Haj Mohammad, N., et al.
Publicado: (2015)

Increased assessment of HER2 in metastatic gastroesophageal cancer patients: a nationwide population-based cohort study
por: Dijksterhuis, Willemieke P. M., et al.
Publicado: (2020)

Prognostic and Predictive Factors for the Curative Treatment of Esophageal and Gastric Cancer in Randomized Controlled Trials: A Systematic Review and Meta-Analysis
por: van den Ende, Tom, et al.
Publicado: (2019)

Phase I Dose Escalation Study with Expansion Cohort of the Addition of Nab-Paclitaxel to Capecitabine and Oxaliplatin (CapOx) as First-Line Treatment of Metastatic Esophagogastric Adenocarcinoma (ACTION Study)
por: Schokker, Sandor, et al.
Publicado: (2019)

Stromal-derived interleukin 6 drives epithelial-to-mesenchymal transition and therapy resistance in esophageal adenocarcinoma
por: Ebbing, Eva A., et al.
Publicado: (2019)

PD-1 The impact of COVID-19 on diagnosis, stage and treatment of esophageal and gastric cancer
por: Bakx, J., et al.
Publicado: (2022)

Chemoradiation induces epithelial‐to‐mesenchymal transition in esophageal adenocarcinoma
por: Steins, Anne, et al.
Publicado: (2019)

Reporting of health-related quality of life in randomized controlled trials involving palliative systemic therapy for esophagogastric cancer: a systematic review
por: ter Veer, Emil, et al.
Publicado: (2018)

Second- and third-line systemic therapy in patients with advanced esophagogastric cancer: a systematic review of the literature
por: ter Veer, Emil, et al.
Publicado: (2016)

A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX
por: Stroes, Charlotte I., et al.
Publicado: (2021)

ADAM10-mediated release of heregulin confers resistance to trastuzumab by activating HER3
por: Ebbing, Eva A., et al.
Publicado: (2016)

Capecitabine, 5-fluorouracil and S-1 based regimens for previously untreated advanced oesophagogastric cancer: A network meta-analysis
por: ter Veer, Emil, et al.
Publicado: (2017)

FOXO transcriptional activity is associated with response to chemoradiation in EAC
por: Creemers, A., et al.
Publicado: (2022)

Minimum biopsy set for HER2 evaluation in gastric and gastro-esophageal junction cancer
por: Gullo, Irene, et al.
Publicado: (2015)

Prediction models for patients with esophageal or gastric cancer: A systematic review and meta-analysis
por: van den Boorn, H. G., et al.
Publicado: (2018)

The Efficacy and Safety of (Neo)Adjuvant Therapy for Gastric Cancer: A Network Meta-analysis
por: van den Ende, Tom, et al.
Publicado: (2019)

COMplot, A Graphical Presentation of Complication Profiles and Adverse Effects for the Curative Treatment of Gastric Cancer: A Systematic Review and Meta-Analysis
por: van den Ende, Tom, et al.
Publicado: (2019)

Gastro-Esophageal Reflux in Children
por: Rybak, Anna, et al.
Publicado: (2017)

Machine Learning for Future Subtyping of the Tumor Microenvironment of Gastro-Esophageal Adenocarcinomas
por: Klein, Sebastian, et al.
Publicado: (2021)

Pre-treatment tumor-infiltrating T cells influence response to neoadjuvant chemoradiotherapy in esophageal adenocarcinoma
por: Goedegebuure, R.S.A., et al.
Publicado: (2021)

Longitudinal immune monitoring of patients with resectable esophageal adenocarcinoma treated with Neoadjuvant PD-L1 checkpoint inhibition
por: van den Ende, Tom, et al.
Publicado: (2023)

Estrogen-related receptor alpha drives mitochondrial biogenesis and resistance to neoadjuvant chemoradiation in esophageal cancer
por: Dings, Mark P.G., et al.
Publicado: (2022)

Spontaneous Regression of Metastatic Lesions of Adenocarcinoma of the Gastro-Esophageal Junction
por: Mitchell, Richard, et al.
Publicado: (2021)

The impact of illness in patients with moderate to severe gastro-esophageal reflux disease
por: El-Dika, Samer, et al.
Publicado: (2005)

Burden of spousal caregivers of stage II and III esophageal cancer survivors 3 years after treatment with curative intent
por: Haj Mohammad, N., et al.
Publicado: (2015)

Determining sensitivity and specificity of HER2 testing in breast cancer using a tissue micro-array approach
por: Dekker, Tim JA, et al.
Publicado: (2012)

Time to reimbursement of novel anticancer drugs in Europe: a case study of seven European countries
por: Post, H.C., et al.
Publicado: (2023)

Two Cases of Esophageal Eosinophilia: Eosinophilic Esophagitis or Gastro-Esophageal Reflux Disease?
por: Yilmaz, Ozlem, et al.
Publicado: (2014)

Endoscopic evaluation of gastro-esophageal reflux disease.
por: Armstrong, D.
Publicado: (1999)

Successes and failures of angiogenesis blockade in gastric and gastro-esophageal junction adenocarcinoma
por: Salati, Massimiliano, et al.
Publicado: (2022)

The potential therapeutic effect of melatonin in gastro-esophageal reflux disease
por: Kandil, Tharwat S, et al.
Publicado: (2010)

Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2)
por: Feilchenfeldt, J, et al.
Publicado: (2015)

Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2)
por: Feilchenfeldt, J, et al.
Publicado: (2015)

The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry
por: Meegdes, Marissa, et al.
Publicado: (2022)

Prevalence and Predictors of Physician-Patient Discordance in Prognostic Perceptions in Advanced Cancer
por: van der Velden, Naomi Cornelia Anna, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_138usm8bem93l5ht8jerv063cf